Home › Companies › 4D Molecular Therapeutics, Inc. › 2025-2026

4D Molecular Therapeutics, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and 4D Molecular Therapeutics, Inc.’s Form 8-K, filed 2026-06-22 (Item 5.07 on EDGAR). Page generated 02 October 2026.

5Reported items
167Asset managers
1,039Fund votes
2026-06-17Meeting date

Proxy season: 2024-2025 2025-2026

Explore 4D Molecular Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by 4D Molecular Therapeutics, Inc.

These tallies are 4D Molecular Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-22 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

4D Molecular Therapeutics, Inc. — official shareholder meeting results, meeting held 2026-06-17
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Nancy Miller-Rich	35,880,028	--	--	1,193,202	6,964,792	Majority: yes
Elect Director: John F. Milligan, Ph.D.	35,778,121	--	--	1,295,109	6,964,792	Majority: yes
Elect Director: Shawn Cline Tomasello, MBA	30,508,706	--	--	6,564,524	6,964,792	Majority: yes
Proposal 3. The Company's stockholders approved, on an advisory, non-binding basis, the named executive officers' compensation as disclosed in the Proxy Statement.	36,065,437	940,414	67,379	--	6,964,792	Majority: yes

Source: 4D Molecular Therapeutics, Inc., Form 8-K, filed with the SEC on 2026-06-22 — read the filing on EDGAR.

How asset managers voted at the 4D Molecular Therapeutics, Inc. 2025-2026 meeting

Each item below shows how the 167 asset managers that disclosed a 4D Molecular Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of 4D Molecular Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Approval, on an advisory, non- binding basis, of the compensation of the Company's named executive officers ("say-on-pay vote").

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 10 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 36,065,437AGAINST: 940,414

4D Molecular Therapeutics, Inc.’s own tally for this item (“Proposal 3. The Company's stockholders approved, on an advisory, non-binding basis, the named executive officers' compensation as disclosed in the Proxy Statement.”): 36,065,437 for, 940,414 against, per its Form 8-K filed 2026-06-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 52,271,648 outstanding shares: 69% for, 2% against (71% of the company cast a for/against vote).

The 166 asset managers below cast 99% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

FOR 99%

FOR: 98.9%AGAINST: 1.1%NOT VOTED: 0.0%

Largest asset managers voting on “Approval, on an advisory, non- binding basis, of the compensation of the Company's named executive officers ("” at 4D Molecular Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
Janus Henderson	6,980,400	0	For
RA CAPITAL MANAGEMENT, L.P.	4,619,802	0	For
Novo Holdings A/S	3,270,000	0	For
BlackRock	3,036,042	30,453	For
Vanguard	3,065,619	2	For
BVF INC/IL	2,879,289	0	For
State Street	2,269,737	3,689	For
Federated Hermes	1,606,252	13,288	For
Goldman Sachs	1,243,984	0	For
Evergreen Quality Fund GP, Ltd.	951,474	0	For
ADAGE CAPITAL PARTNERS GP, L.L.C.	858,456	0	For
JANUS INVESTMENT FUND	843,240	0	For
GEODE CAPITAL MANAGEMENT, LLC	820,973	0	For
Fidelity	782,747	0	For
Charles Schwab	657,514	0	For
Nuveen	564,621	0	For
TIAA	548,991	0	For
ACUTA CAPITAL PARTNERS, LLC	507,801	0	For
Trails Edge Capital Partners, LP	453,014	0	For
Northern Trust	435,860	2,296	For
Dimensional	292,848	0	For
Voya	267,874	0	For
American Century	0	214,528	Against
ArrowMark Colorado Holdings LLC	202,864	0	For
Woodline Partners LP	200,000	0	For

Showing the 25 largest of 166 asset managers. See all 166 in the interactive database.

2. Election of three Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until their successors are elected: John F. Milligan, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 35,778,121WITHHELD: 1,295,109

4D Molecular Therapeutics, Inc.’s own tally for this item (“Elect Director: John F. Milligan, Ph.D.”): 35,778,121 for, 1,295,109 withheld, per its Form 8-K filed 2026-06-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 52,271,648 outstanding shares: 68% for, 2% withheld (71% of the company cast a for/withheld vote).

The 49 asset managers below cast 100% of the shares they voted on this item FOR (10,184,251 for, 0 against).

FOR 97%

FOR: 10,184,251 (97.5%)ABSTAIN: 265,587 (2.5%)

Largest asset managers voting on “Election of three Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until th” at 4D Molecular Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	2,760,672	5,627	For
State Street	1,540,682	1,890	For
BlackRock	1,538,756	0	For
JANUS INVESTMENT FUND	843,240	0	For
Federated Hermes	715,363	0	For
Fidelity	713,535	0	For
TIAA	548,991	0	For
Charles Schwab	328,732	0	For
Dimensional	0	200,177	Abstain
Bridge Builder Trust	198,386	0	For
Northern Trust	179,773	0	For
Voya	109,431	0	For
American Century	107,264	0	For
Equitable	69,943	36,890	For
QUANTITATIVE MASTER SERIES LLC	61,699	0	For
JPMorgan	57,027	0	For
BRIDGEWAY FUNDS INC	50,000	0	For
Lincoln Financial	40,739	4,816	For
ProShares	39,478	0	For
Direxion Shares ETF Trust	37,875	0	For
SEI	30,779	0	For
ETFis Series Trust I	21,946	0	For
AIG/SunAmerica	21,599	0	For
T. Rowe Price	19,733	0	For
Global X	18,995	0	For

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

3. Election of three Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until their successors are elected: Nancy Miller-Rich

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 35,880,028WITHHELD: 1,193,202

4D Molecular Therapeutics, Inc.’s own tally for this item (“Elect Director: Nancy Miller-Rich”): 35,880,028 for, 1,193,202 withheld, per its Form 8-K filed 2026-06-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 52,271,648 outstanding shares: 69% for, 2% withheld (71% of the company cast a for/withheld vote).

The 49 asset managers below cast 100% of the shares they voted on this item FOR (10,182,757 for, 0 against).

FOR 97%

FOR: 10,182,757 (97.4%)ABSTAIN: 267,081 (2.6%)

Largest asset managers voting on “Election of three Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until th” at 4D Molecular Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	2,762,533	3,766	For
State Street	1,540,682	1,890	For
BlackRock	1,538,756	0	For
JANUS INVESTMENT FUND	843,240	0	For
Federated Hermes	715,363	0	For
Fidelity	713,535	0	For
TIAA	548,991	0	For
Charles Schwab	328,732	0	For
Dimensional	0	200,177	Abstain
Bridge Builder Trust	198,386	0	For
Northern Trust	179,773	0	For
Voya	109,431	0	For
American Century	107,264	0	For
Equitable	69,943	36,890	For
QUANTITATIVE MASTER SERIES LLC	61,699	0	For
JPMorgan	57,027	0	For
BRIDGEWAY FUNDS INC	50,000	0	For
Lincoln Financial	40,739	4,816	For
ProShares	39,478	0	For
Direxion Shares ETF Trust	37,875	0	For
SEI	30,779	0	For
ETFis Series Trust I	21,946	0	For
AIG/SunAmerica	21,599	0	For
T. Rowe Price	19,733	0	For
Global X	18,995	0	For

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

4. Election of three Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until their successors are elected: Shawn Cline Tomasello, MBA

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

82% Majority: yes · of votes cast

FOR 82%WITHHELD 18%

FOR: 30,508,706WITHHELD: 6,564,524

4D Molecular Therapeutics, Inc.’s own tally for this item (“Elect Director: Shawn Cline Tomasello, MBA”): 30,508,706 for, 6,564,524 withheld, per its Form 8-K filed 2026-06-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 52,271,648 outstanding shares: 58% for, 13% withheld (71% of the company cast a for/withheld vote).

The 49 asset managers below cast 100% of the shares they voted on this item FOR (7,925,996 for, 0 against).

FOR 76%ABSTAIN 24%

FOR: 7,925,996 (75.8%)ABSTAIN: 2,523,842 (24.2%)

Largest asset managers voting on “Election of three Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until th” at 4D Molecular Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	2,760,658	5,641	For
State Street	1,241	1,541,331	Abstain
BlackRock	1,538,756	0	For
JANUS INVESTMENT FUND	843,240	0	For
Federated Hermes	715,363	0	For
Fidelity	713,535	0	For
TIAA	548,991	0	For
Charles Schwab	328,732	0	For
Dimensional	0	200,177	Abstain
Bridge Builder Trust	147,330	51,056	For
Northern Trust	0	179,773	Abstain
Voya	0	109,431	Abstain
American Century	0	107,264	Abstain
Equitable	69,943	36,890	For
QUANTITATIVE MASTER SERIES LLC	61,699	0	For
JPMorgan	57,027	0	For
BRIDGEWAY FUNDS INC	0	50,000	Abstain
Lincoln Financial	12,539	33,016	Abstain
ProShares	0	39,478	Abstain
Direxion Shares ETF Trust	0	37,875	Abstain
SEI	30,779	0	For
ETFis Series Trust I	0	21,946	Abstain
AIG/SunAmerica	0	21,599	Abstain
T. Rowe Price	19,733	0	For
Global X	18,995	0	For

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

5. Ratification of the appointment, by the Audit Committee of the Company's Board of Directors, of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026.

AUDIT-RELATED

99.9% fund support · no official result

FOR 99.9%

The 49 asset managers below cast 99.9% of the shares they voted on this item FOR (10,449,779 for, 59 against).

FOR: 10,449,779 (100.0%)AGAINST: 59 (0.0%)

Largest asset managers voting on “Ratification of the appointment, by the Audit Committee of the Company's Board of Directors, of Pricewaterhous” at 4D Molecular Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	2,766,299	0	For
State Street	1,542,513	59	For
BlackRock	1,538,756	0	For
JANUS INVESTMENT FUND	843,240	0	For
Federated Hermes	715,363	0	For
Fidelity	713,535	0	For
TIAA	548,991	0	For
Charles Schwab	328,732	0	For
Dimensional	200,177	0	For
Bridge Builder Trust	198,386	0	For
Northern Trust	179,773	0	For
Voya	109,431	0	For
American Century	107,264	0	For
Equitable	106,833	0	For
QUANTITATIVE MASTER SERIES LLC	61,699	0	For
JPMorgan	57,027	0	For
BRIDGEWAY FUNDS INC	50,000	0	For
Lincoln Financial	45,555	0	For
ProShares	39,478	0	For
Direxion Shares ETF Trust	37,875	0	For
SEI	30,779	0	For
ETFis Series Trust I	21,946	0	For
AIG/SunAmerica	21,599	0	For
T. Rowe Price	19,733	0	For
Global X	18,995	0	For

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

Largest 4D Molecular Therapeutics, Inc. shareholders voting in 2025-2026

Ranked by the number of 4D Molecular Therapeutics, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 52,271,648 shares outstanding at the time of that meeting.

Top 4D Molecular Therapeutics, Inc. shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	Janus Henderson	13.35%
2	RA CAPITAL MANAGEMENT, L.P.	8.84%
3	Novo Holdings A/S	6.26%
4	BlackRock	5.87%
5	Vanguard	5.86%
6	BVF INC/IL	5.51%
7	State Street	4.35%
8	Federated Hermes	3.10%
9	Goldman Sachs	2.38%
10	Evergreen Quality Fund GP, Ltd.	1.82%

Reported 4D Molecular Therapeutics, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

4D Molecular Therapeutics, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
BVF PARTNERS L P/IL	10.23%	13G
JANUS HENDERSON GROUP PLC	10.04%	13G
Goldman Sachs	8.05%	13F
BlackRock	7.93%	13F
Novo Holdings A/S	6.98%	13G
Vanguard Group	5.92%	13F
Biotechnology Value Fund, L.P.	5.51%	DEF14A
State Street	5.18%	13F
David Kirn, M.D.	3.17%	DEF14A
Geode Capital	2.04%	13F

Percentages above are of 52,271,648 shares outstanding, as reported by 4D Molecular Therapeutics, Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from 4D Molecular Therapeutics, Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At 4D Molecular Therapeutics, Inc.'s shareholder meeting held 2026-06-17, in the 2025-2026 proxy season, 167 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,039 separate fund positions. Their filings are grouped here into 5 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — Approval, on an advisory, non- binding basis, of the compensation of the Company's named… — FOR was 97% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: 4D Molecular Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-22.

4D Molecular Therapeutics, Inc. proxy season coverage: 2024-2025 · 2025-2026 (this page).